Skip to search formSkip to main contentSkip to account menu

ixazomib

Known as: {(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic Acid 
An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

15 relations

Broader (4)

Antineoplastic AgentsBoron CompoundsGlycineProtease Inhibitors

Narrower (3)

MLN 9708MLN2238ixazomib citrate
NCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisProteasome Function InhibitionProteasome Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome.
2018
2018
Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
Review
2017
Review
2017
Novel Therapies in Light Chain Amyloidosis
2017
2017
Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Background: Maintenance lenalidomide (Len) use in the post autologous stem cell transplant (ASCT) setting has demonstrated a… 
2017
2017
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma
Despite advances in deciphering the molecular pathogenesis of diffuse large B-cell lymphoma (DLBCL), patients with relapsed… 
2017
2017
Ixazomib enhances parathyroid hormone–induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor
The proteasome inhibitor ixazomib (Izb) dissociates β-catenin from the PTH receptor to enhance PTH stimulation of β-catenin/TCF… 
2016
2016
Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment
Neuroblastoma (NB) is the most common extracranial malignant solid tumor seen in children and continues to lead to the death of… 
Review
2016
Review
2016
Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents
Advances in therapy in multiple myeloma have resulted in significant improvements in patient outcomes; however, relapse remains… 
2016
2016
Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma…
Background Frontline ASCT is the standard of care for patients with symptomatic NDMM less than 66 years of age. 3-drug… 
Review
2005
Review
2005
Stem cell transplantation in multiple myeloma
Single autologous transplantation High-dose treatment (HDT) with autologous stem cell transplantation (ASCT) has been shown to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)